
    
      The duration of the study for a patient will include a period for screening of up to 21 days
      and 3-month post treatment follow up. The cycle duration is 28 days. Patients will continue
      treatment until disease progression, unacceptable adverse events, consent withdrawal, or any
      other reason.
    
  